Omeros Corporation (OMER)

[TheFinalCD]

OMER Omeros reports positive results from phase 2 trial

Omeros (OMER) announces that it achieved 50% higher plasma concentrations in its phase 2a trial of OMS824, the firm's phosphodiesterase 10 (PDE10) inhibitor without additional side effects.
The product inhibits PDE10, an enzyme expressed in the brain that is linked to diseases that affect cognition (Huntington's, schizophrenia).
The results indicate that OMS824 can be administered with standard antipsychotic medication at a concentration that can achieve a high degree of PDE10 interaction.
The FDA designated Orphan Drug status to OMS824 for Huntington's disease. A Fast Track application is currently under agency review.
Press release